PeriCyto: A Companion Diagnostics for Immune Checkpoint Inhibitors

Prediction of the efficacy of cancer immunotherapy using the tumor-targeting activity of T cells in peripheral blood.

A Business Partnership Proposal

Advantages

  • Diagnostic methods using peripheral blood: Relatively minimally invasive; Low cost; Realtime monitoring

Background

While some immune checkpoint inhibitors (ICI) have been shown to have significant effects on antitumor immune responses, the response rates of those currently on the market are not very high.  In general, the response rate of anti-PD-1 antibody drugs is low (i.e., Nivolumab is said to be around 20%), so clinical development combined with patient stratification by companion diagnostics is being attempted.  For example, Pembrolizumab, a drug for the treatment of non-small cell lung cancer, has been approved in combination with companion diagnostics (CoDx) that test for PD-L1 positivity in lung cancer tissue.  However, since this requires invasive testing, there is a need for a simpler and more accurate method of predicting treatment efficacy.

Technology Overview

This technology, named PeriCyto ‒ peripheral T cell cytotoxicity, is capable of predicting the efficacy and severe adverse events of immunotherapy in cancer patients.  The above diagnosis can be achieved with a very simple method. First, T cells collected from the peripheral blood of cancer patients are co-cultured with tumor cells and dual specificity molecules (engagers) such as BiTE (Bispecific T-cell Engager) for two days, and then the cytotoxic activity of the patient’s peripheral blood-derived T cells is measured.

Publication(s)

K. Iwahori, et al. “Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment.” Scientific Reports volume 9, Article number: 2636 (2019).
https://doi.org/10.1038/s41598-019-39345-5

Patent(s)

PCT/JP2018/024770
Note:   The PCT application is published on WIPO website as WO2019/004415 in Japanese, and applied for transition application to CN, EP, JP, US (JP: Granted, Others: Pending).

Principal Investigator & Academic Institution

Kota IWAHORI, MD, PhD (Specially Appointed Associate Professor, Osaka University, Japan)

Expectations

This is Not a proposal for an IP license, but for business partnership/collaboration with Osaka University and Diagnostics Companies on the PeriCyto CoDx technology, and an inquiry about your interests and wishes.

Business Partnership

Tech Manage Corp. is looking for the partners which are developing ICI drugs and interested in trying this invention as a CoDx technology for developing stage medicines.  We can set up a meeting between the parties involved.  If you have any other questions, please feel free to ask us anything, anytime.

 

Project Code: JT-03945

 

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.